Silica-Based Polymeric Gels as Platforms for Delivery of Phosphonate Pharmaceutics
This chapter focuses on polymeric gel drug delivery systems used for initial immobilization and subsequent controlled release of active pharmaceutical ingredients. The primary focus is on phosphonate-based drugs, which are extensively used for a variety of medicinal applications and pathological conditions. Their most recognizable use is for osteoporosis drugs with the common names: medronate, chlodronate, etidronate, alendronate, zoledronate, obadronate, ibandronate, neridronate, etc. Herein, we present a concise literature overview of this research field, presenting research results on immobilization of phosphonates onto silica-based polymeric gels, with the goal to achieve controlled release of these ingredients into biological fluids.
KeywordsSilica Gels Controlled release Phosphonates Osteoporosis
K. E. Papathanasiou thanks the Onassis Foundation for a doctoral scholarship. K. D. Demadis thanks the EU for funding the Research Program SILICAMPS-153, under the ERA.NET-RUS Pilot Joint Call for Collaborative S&T projects.
- Demadis KD (2008) Silica scale inhibition relevant to desalination technologies: progress and recent developments. In: Delgado DJ, Moreno P (eds) Desalination research progress. Nova Science Publishers, Inc., New York, pp 249–259Google Scholar
- Dunford JE, Thomspson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl disphosphate syntase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharm Exp Ther 296:235–242Google Scholar
- Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 96:133–138CrossRefPubMedGoogle Scholar
- Fleisch H, Reszka A, Rodan G, Rogers G (2002) Bisphosphonates: mechanisms of action. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology. Academic Press, San Diego, pp 1361–1385Google Scholar
- Hirabayashi H, Takahashi T, Fujisaki J, Masunaga T, Sato S, Hiroi J, Tokunaga Y, Kimura S, Hata T (2001) Bone specific delivery and sustained release of diclofenac, a non- steroidal anti-inflammatory drug, via bisphosphonic prodrug based on osteotropic drug delivery system (ODDS). J Control Release 70:183–191CrossRefPubMedGoogle Scholar
- Hughes LG, Vick TA, Wang JH (2004) Coated Implants. European Patent 1250164Google Scholar
- Lehenkari PP, Kellinsalmi M, Näpänkangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ, Azhayev A, Väänänen HK, Hassinen IE (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255–1262CrossRefPubMedGoogle Scholar
- Mashkevich BO (ed) (2007) Drug delivery research advances. Nova Science Publishers Inc., New YorkGoogle Scholar
- Patwardhan SV, Clarson SJ, Perry CC (2005) On the role(s) of additives in bioinspired silicification. Chem Commun 1113–1121Google Scholar
- Thompson WJ, Thompson DD, Anderson PS, Rodan GA (1989) Polymalonic acids as bone affinity agents. European Patent 0341961Google Scholar
- Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999) Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491–494CrossRefPubMedGoogle Scholar